Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone

Sage Therapeutics will jettison 40% of its workforce as the company navigates a future for its Biogen-partnered drug after the therapy was rejected as a treatment for major depressive disorder (MDD).